Clinical Trial Detail

NCT ID NCT02441946
Title A Phase 2 Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Eli Lilly and Company
Indications

Her2-receptor negative breast cancer

Therapies

Abemaciclib

Loperamide

Anastrozole

Age Groups: adult

Additional content available in CKB BOOST